問卷

TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Otolaryngology

Taipei Medical University Hospital (在職)

Division of Cardiovascular Diseases

更新時間:2023-09-19

楊宗霖Yang, Tsung-Lin
  • Co-Principal Investigator
  • Clinical Trial Experience (year) 8 years

篩選

List

23Cases

2022-10-01 - 2027-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Not yet recruiting11Sites

2024-02-27 - 2030-01-27

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Recruiting1Sites

Suspended15Sites

2023-04-01 - 2032-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2022-12-01 - 2025-02-26

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting4Sites

Terminated1Sites

2022-01-19 - 2027-10-20

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting2Sites

Recruiting5Sites

2023-05-08 - 2027-07-02

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting5Sites

2020-03-17 - 2024-05-02

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting2Sites

Recruiting6Sites

2018-11-19 - 2022-12-01

Phase III

An International, Double-blind, Randomised, Placebo-Controlled Phase III Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)
  • Condition/Disease

    Heart Failure With Preserved Ejection Fraction (HFpEF)

  • Test Drug

    dapagliflozin film-coated tablets

Participate Sites
15Sites

Recruiting13Sites

江晨恩
Taipei Veterans General Hospital

Division of Cardiovascular Diseases

2015-12-01 - 2021-05-20

Phase I/II

A Phase 1b/2 Study of PEP503 (Radioenhancer) with Radiotherapy in Combination with Concurrent Chemotherapy for Patients with Head and Neck Cancer
  • Condition/Disease

    Head and Neck Cancer

  • Test Drug

    PEP503

Participate Sites
4Sites

Recruiting3Sites

Terminated1Sites

趙坤山
China Medical University Hospital

Division of Hematology & Oncology

2017-12-01 - 2018-06-03

Phase III

A Phase 1b/3 Multicenter, Randomized Trial of Talimogene Laherparepvec in combination with Pembrolizumab for theTreatment of Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
  • Condition/Disease

    Squamous Cell Carcinoma of the Head and Neck

  • Test Drug

    IMLYGIC

Participate Sites
6Sites

Terminated6Sites

1 2 3